ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.

ABSTRACT:

Background

Development of new therapies for Alzheimer's disease (AD) is increasingly focused on more mildly affected populations, and requires new assessment and outcome strategies. Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairment. To respond to these assessment challenges, we developed a measurement approach based on established scale items that exhibited change in previous amnestic Mild Cognitive Impairment (aMCI) trials.

Methods

Partial least squares regression with a longitudinal clinical decline model identified items from commonly used clinical scales with the highest combined sensitivity to change over time in aMCI and weighted these items according to their relative contribution to detecting clinical progression in

SUBMITTER: Wang J 

PROVIDER: S-EPMC5013117 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature